{"lc": 1, "type": "constructor", "id": ["langchain", "schema", "document", "Document"], "kwargs": {"metadata": {"producer": "iLovePDF", "creator": "PDFMiner", "creationdate": "", "moddate": "2025-09-14T06:45:35+00:00", "total_pages": 280, "source": "./oasis_manual.pdf"}, "page_content": "o \no  has no dead space, \no  has no avascular tissue, \no  has no signs or symptoms of infection, \no  has open wound edges. \n\n\u2022  Code 2, Early/partial granulation, when all the following are true: \no  \u226525% of the wound bed is covered with granulation tissue, \no  < 25% of the wound bed is covered with avascular tissue, \no  may have dead space,  \no  wound bed has no signs or symptoms of infection, \no  wound has open edges. \n\n\u2022  Code 3, Not healing, when any of the following are true: \n\nthe wound bed is clean but non-granulating. \n\no  The wound bed has \u226525% avascular tissue. \no  signs/symptoms of infection. \no \no  wound edges are closed/hyperkeratotic. \no  persistent failure to improve despite appropriate comprehensive wound management. \no  Dash is not a valid response for this item. \n\nOASIS-E1 \nEffective 01/01/2025 \nCenters for Medicare & Medicaid Services \n\n208\n\fChapter 3 \n\nSection N: Medications \n\nSECTION N: MEDICATIONS \nIntroduction \nThe intent of the items in this section is to record whether: \n\n\u2022 \n\nthe patient is taking any medications in high-risk drug classes, there is a patient-specific indication noted and \nthe patient/caregiver has been educated about the high-risk medications. \n\n\u2022  a drug regimen review was conducted. \n\n\u2022 \n\nthe patient can manage oral and injectable medications. \n\nN0415: High-Risk Drug Classes: Use and Indication \n\nItem Intent \n\nThis item identifies if the patient is taking any prescribed medications in the specified drug classes and whether \nthe patient-specific indication was noted for all medications in the drug class. \n\nItem Rationale \n\nPatients who take medications in these high-risk drug classes are at risk for side effects that can adversely affect \nhealth, safety, and quality of life. \n\nOASIS-E1 \nEffective 01/01/2025 \nCenters for Medicare & Medicaid Services \n\n209", "type": "Document"}}